



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form USPTO USPTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10557-014-10577814
		Filing Date	April 28, 2006
		First Named Inventor	J. Lieberman et al.
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet 1 of 4		Attorney Docket Number	033393/55222
U.S. PATENT DOCUMENTS			
Examiner Initials	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY
	1	US-6,228,642 B1	05-08-2001
FOREIGN PATENT DOCUMENTS			
Examiner Initials	Cite No. ¹	Foreign Patent Document Kind Code ² Number ³ (if known)	Publication Date MM-DD-YYYY
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
	2	ASHKENAZI, A. and DIXIT, V.M. <i>Science</i> 281:1305-1308 (1998)	
	3	CHIU & RANA, <i>RNA</i> 9:1034-1048 (2003)	
	4	DEL ZOPPO, G.J., K.M.A. Welch, L.R. Caplan, D.J. Reis, et al., (Eds.) pp.217-220 Academic Press, San Diego (1997)	
	5	FLOYD & CARNEY, <i>Ann. Neurol.</i> 32:S22-S27 (1992).	
	6	GREEN, D.R. and EVAN, G.I. <i>Cancer Cell</i> 1:19-30 (2002)	
	7	HAMADA et al., <i>Antisense Nucleic Acid Drug Dev.</i> 12:301-309 (2002)	
	8	HERWEIJER & WOLFF, <i>Gene Therapy</i> 10:453-458 (2003)	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10552-014 10577814
				Filing Date	April 28, 2006
				First Named Inventor	J. Lieberman et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	033393/55222
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			²
	9	HEYMAN et al., <i>Curr. Opin. Crit. Care</i> . 8(6):526-34. (2002)			
	10	JACKSON et al., <i>Nat. Biotechnol.</i> 21(6):635-637 (2003)			
	11	LIU, K.D., <i>Crit. Care Med.</i> 31(8)(Suppl.):S572-S581 (2003)			
	12	LEE et al., <i>Am. J. Physiol. Heart Circ. Physiol.</i> 284:H456-H463 (2003)			
	13	LEWIS et al., <i>Nature Genetics</i> 32:107-108 (2002)			
	14	MARUYAMA et al., <i>J. Gene. Med.</i> 4:333-341 (2002)			
	15	MARUYAMA et al., <i>Hum. Gene Ther.</i> 13:455-468 (2002)			
	16	MATTSON, M.P. <i>Nat. Rev. Mol. Cell. Biol.</i> 1:120-128 (2002)			
	17	MCCAFFREY et al., <i>Nature</i> 418:38-39 (2002)			
	18	MENÈ et al., <i>J. Nephrol.</i> 16:186-195 (2003)			
	19	MEIER, P., et al., <i>Nature</i> 407:796-801 (2000)			
	20	MOGI et al., <i>Lab. Invest.</i> 81(2):177-184 (2001)			
	21	NAGATA & SUDA, <i>Immunology Today</i> 16(1):39-43 (1995)			
Examiner Signature				Date Considered	

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/557,814 10/577814
		Filing Date	April 28, 2006
		First Named Inventor	J. Lieberman et al.
		Group Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet	3	of	4
		Attorney Docket Number	033393/55222
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	22	NANSEN et al., <i>Blood</i> 99(4):1237-1245 (2002)	
	23	NOGAE et al., <i>J. Am. Soc. Nephrol.</i> 9(4):620-631 (1998)	
	24	ORTIZ et al., <i>Current Drug Targets - Immune, Endocrine & Metabolic Disorders</i> 2:181-192 (2002)	
	25	PASCHEN, W., <i>J. Cereb. Blood Flow Metab.</i> 23(7):773-779 (2003)	
	26	PRAKAS et al., <i>Ren. Fail.</i> 25(2):225-233 (2003)	
	27	RATHMELL, J.C. and THOMPSON, C.B. <i>Cell</i> 109 (Suppl.): S97-S107 (2002)	
	28	REITER et al., <i>Ann. N.Y. Acad. Sci.</i> 993:35-47 (2003)	
	29	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) <i>Lancet</i> , 347: 1398	
	30	SATA & WALSH, <i>J. Biol. Chem.</i> 273(50):33103-33106 (1998)	
	31	SCAFFIDI et al., <i>J. Biol. Chem.</i> 274(3):1541-1548 (1999)	
	32	SLEDZ et al., <i>Nat. Cell Biol.</i> 5(9):834-839 (2003)	
	33	SONG et al., <i>Nat. Med.</i> 9(3):347-351 (2003)	
Examiner Signature			Date Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. 10051336.2

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/557,814 10/577814
		Filing Date	April 28, 2006
		First Named Inventor	J. Lieberman et al.
		Group Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
		Attorney Docket Number	033393/55222
Sheet	4	of	4
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
	34	SØRENSEN, Dag R. et al., <i>J. Mol. Biol.</i> ; 327:761-766 (2003)	
	35	TEOH & FARRELL, <i>J. Gastroenterol. Hepatol.</i> 18:891-902 (2003)	
	36	THADHANI et al., <i>N. Engl. J. Med.</i> 334:1448-60 (1996)	
	37	VAUX, D.L. and KORSMEYER, S.J. <i>Cell</i> 96:245-254 (1999)	
	38	VERMUELEN, K., et al. <i>Cell Prolif.</i> 36:165-175 (2003)	
	39	WALL, Nathan R. et al., <i>The Lancet</i> ; 362:1401-1403 (2003)	
	40	WATANABE-FUKUNAGA, R., et al., <i>J. Immunol.</i> , 148:1274-1279 (1992)	
	41	ZHANG et al., <i>Hum. Gene Ther.</i> 10:1735-1737 (1999)	
	42	ZHANG et al., <i>J. Biol. Chem.</i> 277(40):37430-37438 (2002)	
	43	ZÖRNIG, M., et al., <i>Biochim. Biophys. Acta</i> 1551:F1-F37 (2001)	
Examiner Signature	/Sean McGarry/		Date Considered 09/28/2009

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.